

AMENDMENTS TO THE CLAIMS

This listing replaces all prior versions and listings of claims in this application.

Listing of Claims

1.-57. Cancelled

58. (Previously Presented) A composition comprising:

- i) a beta-2 adrenoceptor agonist;
- ii) an aminosugar selected from the group consisting of glucosamine, mannosamine, salts and derivatives thereof, wherein the derivatives thereof is selected from the group consisting of wherein the amino group and/or hydroxyl group of the aminosugar is alkylated, arylated or acylated, and wherein the anomeric, 2-, 3-, 4-, or 6-position is sulphated or phosphorylated; and
- iii) one or more acceptable excipients or carriers.

59. (Previously Presented) The composition according to claim 58, wherein the beta-2 adrenoceptor agonist is selected from the group consisting of bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline, dioxethedrine, dopexamine, ephedrine, epinephrine, etafedrine, ethylnorepinephrine, fenoterol, formoterol, hexoprenaline, isoetarine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine, pirbuterol, procaterol, protokylol, reproterol, rimiterol, ritodrine, salbutamol, salmeterol, soterenol, terbutaline, tretoquinol, tulobuterol, derivatives and salts thereof.

60. (Previously Presented) The composition according to claim 58, wherein the aminosugar is glucosamine hydrochloride or glucosamine sulfate.

61. (Currently Amended) The composition according to claim ~~58~~ 59, wherein the beta-2 adrenoceptor agonist is salbutamol sulfate, terbutaline sulfate or formoterol fumarate dihydrate.

62 – 63. Cancelled

64. *(Previously Presented)* The composition according to claim 58 in a form selected from the group consisting of oral formulation, topical formulation, transdermal formulation, and parenteral formulation.

65 – 80. *Cancelled*